Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence.

O'Reilly D, Fou L, Hasler E, Hawkins J, O'Connell S, Pelone F, Callaway M, Campbell F, Capel M, Charnley R, Corrie P, Elliot D, Goodburn L, Jewell A, Joharchi S, McGeeney L, Mukherjee S, Oppong K, Whelan P, Primrose J, Neoptolemos J.

Pancreatology. 2018 Sep 28. pii: S1424-3903(18)30689-6. doi: 10.1016/j.pan.2018.09.012. [Epub ahead of print] Review.

PMID:
30292643
2.

The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer.

Gootjes EC, Bakkerus L, Ten Tije AJ, Witteveen PO, Buffart TE, Bridgewater JA, Primrose JN, Verhoef C, Verheul HMW.

Eur J Cancer. 2018 Nov;103:160-164. doi: 10.1016/j.ejca.2018.07.012. Epub 2018 Sep 19.

PMID:
30243064
3.

Surgeons' assessment versus risk models for predicting complications of hepato-pancreato-biliary surgery (HPB-RISC): a multicenter prospective cohort study.

Samim M, Mungroop TH, AbuHilal M, Isfordink CJ, Molenaar QI, van der Poel MJ, Armstrong TA, Takhar AS, Pearce NW, Primrose JN, Harris S, Verkooijen HM, van Gulik TM, Hagendoorn J, Busch OR, Johnson CD, Besselink MG; HPB-RISC Study Group.

HPB (Oxford). 2018 Sep;20(9):809-814. doi: 10.1016/j.hpb.2018.02.635. Epub 2018 Apr 17.

PMID:
29678364
4.

Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial.

Shinkins B, Primrose JN, Pugh SA, Nicholson BD, Perera R, James T, Mant D.

Br J Surg. 2018 May;105(6):658-662. doi: 10.1002/bjs.10819. Epub 2018 Mar 26.

PMID:
29579327
5.

Laparoscopic versus open major hepatectomy: a systematic review and meta-analysis of individual patient data.

Kasai M, Cipriani F, Gayet B, Aldrighetti L, Ratti F, Sarmiento JM, Scatton O, Kim KH, Dagher I, Topal B, Primrose J, Nomi T, Fuks D, Abu Hilal M.

Surgery. 2018 May;163(5):985-995. doi: 10.1016/j.surg.2018.01.020. Epub 2018 Mar 16. Review.

PMID:
29555197
6.

Long non-coding RNAs within the tumour microenvironment and their role in tumour-stroma cross-talk.

Del Vecchio F, Lee GH, Hawezi J, Bhome R, Pugh S, Sayan E, Thomas G, Packham G, Primrose J, Pichler M, Mirnezami A, Calin G, Bullock M.

Cancer Lett. 2018 May 1;421:94-102. doi: 10.1016/j.canlet.2018.02.022. Epub 2018 Feb 17.

PMID:
29458141
7.

Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer.

Bhome R, Del Vecchio F, Lee GH, Bullock MD, Primrose JN, Sayan AE, Mirnezami AH.

Cancer Lett. 2018 Apr 28;420:228-235. doi: 10.1016/j.canlet.2018.02.002. Epub 2018 Feb 7.

8.

Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression.

Bhome R, Goh RW, Bullock MD, Pillar N, Thirdborough SM, Mellone M, Mirnezami R, Galea D, Veselkov K, Gu Q, Underwood TJ, Primrose JN, De Wever O, Shomron N, Sayan AE, Mirnezami AH.

Aging (Albany NY). 2017 Dec 28;9(12):2666-2694. doi: 10.18632/aging.101355.

9.

Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial.

Pugh S, Thiébaut R, Bridgewater J, Grisoni ML, Moutasim K, Rousseau F, Thomas GJ, Griffiths G, Liebaert F, Primrose J, Laurent-Puig P.

Oncotarget. 2017 Sep 27;8(55):93856-93866. doi: 10.18632/oncotarget.21291. eCollection 2017 Nov 7.

10.

Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study.

van Hilst J, de Rooij T, Klompmaker S, Rawashdeh M, Aleotti F, Al-Sarireh B, Alseidi A, Ateeb Z, Balzano G, Berrevoet F, Björnsson B, Boggi U, Busch OR, Butturini G, Casadei R, Del Chiaro M, Chikhladze S, Cipriani F, van Dam R, Damoli I, van Dieren S, Dokmak S, Edwin B, van Eijck C, Fabre JM, Falconi M, Farges O, Fernández-Cruz L, Forgione A, Frigerio I, Fuks D, Gavazzi F, Gayet B, Giardino A, Bas Groot K, Hackert T, Hassenpflug M, Kabir I, Keck T, Khatkov I, Kusar M, Lombardo C, Marchegiani G, Marshall R, Menon KV, Montorsi M, Orville M, de Pastena M, Pietrabissa A, Poves I, Primrose J, Pugliese R, Ricci C, Roberts K, Røsok B, Sahakyan MA, Sánchez-Cabús S, Sandström P, Scovel L, Solaini L, Soonawalla Z, Souche FR, Sutcliffe RP, Tiberio GA, Tomazic A, Troisi R, Wellner U, White S, Wittel UA, Zerbi A, Bassi C, Besselink MG, Abu Hilal M; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS).

Ann Surg. 2017 Nov 2. doi: 10.1097/SLA.0000000000002561. [Epub ahead of print]

PMID:
29099399
11.

The Southampton Consensus Guidelines for Laparoscopic Liver Surgery: From Indication to Implementation.

Abu Hilal M, Aldrighetti L, Dagher I, Edwin B, Troisi RI, Alikhanov R, Aroori S, Belli G, Besselink M, Briceno J, Gayet B, D'Hondt M, Lesurtel M, Menon K, Lodge P, Rotellar F, Santoyo J, Scatton O, Soubrane O, Sutcliffe R, Van Dam R, White S, Halls MC, Cipriani F, Van der Poel M, Ciria R, Barkhatov L, Gomez-Luque Y, Ocana-Garcia S, Cook A, Buell J, Clavien PA, Dervenis C, Fusai G, Geller D, Lang H, Primrose J, Taylor M, Van Gulik T, Wakabayashi G, Asbun H, Cherqui D.

Ann Surg. 2018 Jul;268(1):11-18. doi: 10.1097/SLA.0000000000002524.

PMID:
29064908
12.

Are the current difficulty scores for laparoscopic liver surgery telling the whole story? An international survey and recommendations for the future.

Halls MC, Cherqui D, Taylor MA, Primrose JN, Abu Hilal M; Collaborators of The Difficulty of Laparoscopic Liver Surgery Survey.

HPB (Oxford). 2018 Mar;20(3):231-236. doi: 10.1016/j.hpb.2017.08.028. Epub 2017 Sep 29.

PMID:
28969960
13.

IL-12 and IL-15 induce the expression of CXCR6 and CD49a on peripheral natural killer cells.

Hydes T, Noll A, Salinas-Riester G, Abuhilal M, Armstrong T, Hamady Z, Primrose J, Takhar A, Walter L, Khakoo SI.

Immun Inflamm Dis. 2018 Mar;6(1):34-46. doi: 10.1002/iid3.190. Epub 2017 Sep 27.

14.

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23. Erratum in: Lancet Gastroenterol Hepatol. 2017 Sep;2(9):e6.

15.

A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent.

Mant D, Gray A, Pugh S, Campbell H, George S, Fuller A, Shinkins B, Corkhill A, Mellor J, Dixon E, Little L, Perera-Salazar R, Primrose J.

Health Technol Assess. 2017 May;21(32):1-86. doi: 10.3310/hta21320.

16.

What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial.

Shinkins B, Nicholson BD, James T, Pathiraja I, Pugh S, Perera R, Primrose J, Mant D.

Health Technol Assess. 2017 Apr;21(22):1-60. doi: 10.3310/hta21220. Review.

17.

A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer.

West MA, Roman A, Sayan E, Primrose JN, Wedge SR, Underwood TJ, Mirnezami AH.

Crit Rev Oncol Hematol. 2017 Apr;112:80-102. doi: 10.1016/j.critrevonc.2017.02.008. Epub 2017 Feb 16. Review.

PMID:
28325268
18.

The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: Results from the FACS trial.

Shinkins B, Nicholson BD, Primrose J, Perera R, James T, Pugh S, Mant D.

PLoS One. 2017 Mar 10;12(3):e0171810. doi: 10.1371/journal.pone.0171810. eCollection 2017.

19.

Outcome and Learning Curve in 159 Consecutive Patients Undergoing Total Laparoscopic Hemihepatectomy.

van der Poel MJ, Besselink MG, Cipriani F, Armstrong T, Takhar AS, van Dieren S, Primrose JN, Pearce NW, Abu Hilal M.

JAMA Surg. 2016 Oct 1;151(10):923-928. doi: 10.1001/jamasurg.2016.1655.

PMID:
27383568
20.

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

Garcia E, Hayden A, Birts C, Britton E, Cowie A, Pickard K, Mellone M, Choh C, Derouet M, Duriez P, Noble F, White MJ, Primrose JN, Strefford JC, Rose-Zerilli M, Thomas GJ, Ang Y, Sharrocks AD, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Sci Rep. 2016 Sep 7;6:32417. doi: 10.1038/srep32417.

21.

Propensity score-based analysis of outcomes of laparoscopic versus open liver resection for colorectal metastases.

Cipriani F, Rawashdeh M, Stanton L, Armstrong T, Takhar A, Pearce NW, Primrose J, Abu Hilal M.

Br J Surg. 2016 Oct;103(11):1504-12. doi: 10.1002/bjs.10211. Epub 2016 Aug 3.

PMID:
27484847
22.

Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.

Pugh SA, Bowers M, Ball A, Falk S, Finch-Jones M, Valle JW, O'Reilly DA, Siriwardena AK, Hornbuckle J, Rees M, Rees C, Iveson T, Hickish T, Maishman T, Stanton L, Dixon E, Corkhill A, Radford M, Garden OJ, Cunningham D, Maughan TS, Bridgewater JA, Primrose JN.

Br J Cancer. 2016 Aug 9;115(4):420-4. doi: 10.1038/bjc.2016.208. Epub 2016 Jul 19.

23.

Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.

Bhome R, Al Saihati HA, Goh RW, Bullock MD, Primrose JN, Thomas GJ, Sayan AE, Mirnezami AH.

New Horiz Transl Med. 2016 Jan;3(1):9-21.

24.

Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.

Noble F, Mellows T, McCormick Matthews LH, Bateman AC, Harris S, Underwood TJ, Byrne JP, Bailey IS, Sharland DM, Kelly JJ, Primrose JN, Sahota SS, Bateman AR, Thomas GJ, Ottensmeier CH.

Cancer Immunol Immunother. 2016 Jun;65(6):651-62. doi: 10.1007/s00262-016-1826-5. Epub 2016 Mar 28.

25.

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.

Matthews LM, Noble F, Tod J, Jaynes E, Harris S, Primrose JN, Ottensmeier C, Thomas GJ, Underwood TJ.

Br J Cancer. 2015 Dec 22;113(12):1746. doi: 10.1038/bjc.2015.460. No abstract available.

26.

Blood CEA levels for detecting recurrent colorectal cancer.

Nicholson BD, Shinkins B, Pathiraja I, Roberts NW, James TJ, Mallett S, Perera R, Primrose JN, Mant D.

Cochrane Database Syst Rev. 2015 Dec 10;(12):CD011134. doi: 10.1002/14651858.CD011134.pub2. Review.

27.

Natural killer cell maturation markers in the human liver and expansion of an NKG2C+KIR+ population.

Hydes T, Abuhilal M, Armstrong T, Primrose J, Takhar A, Khakoo S.

Lancet. 2015 Feb 26;385 Suppl 1:S45. doi: 10.1016/S0140-6736(15)60360-9.

PMID:
26312867
28.

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial.

Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen HJ, Lohse AW, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H.

BMC Cancer. 2015 Jul 31;15:564. doi: 10.1186/s12885-015-1498-0.

29.

Site and Stage of Colorectal Cancer Influence the Likelihood and Distribution of Disease Recurrence and Postrecurrence Survival: Data From the FACS Randomized Controlled Trial.

Pugh SA, Shinkins B, Fuller A, Mellor J, Mant D, Primrose JN.

Ann Surg. 2016 Jun;263(6):1143-7. doi: 10.1097/SLA.0000000000001351.

30.

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.

McCormick Matthews LH, Noble F, Tod J, Jaynes E, Harris S, Primrose JN, Ottensmeier C, Thomas GJ, Underwood TJ.

Br J Cancer. 2015 Jun 30;113(1):107-18. doi: 10.1038/bjc.2015.179. Epub 2015 Jun 25. Review. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1746.

31.

A top-down view of the tumor microenvironment: structure, cells and signaling.

Bhome R, Bullock MD, Al Saihati HA, Goh RW, Primrose JN, Sayan AE, Mirnezami AH.

Front Cell Dev Biol. 2015 May 29;3:33. doi: 10.3389/fcell.2015.00033. eCollection 2015. Review.

32.

Clinician engagement is critical to public engagement with clinical trials.

Stock CJ, Carley N, Hickman B, Primrose J, Ayres A, McGrath C, Edwards CJ, Faust SN.

BMJ. 2015 Jun 12;350:h3140. doi: 10.1136/bmj.h3140. No abstract available.

PMID:
26071322
33.

Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases.

Primrose JN, Cunningham D, Garden OJ, Maughan TS, Pugh SA, Stanton L, Falk SJ, Rees M, Finch-Jones M, Valle JW, O'Reilly D, Hornbuckle J, Hickish T, Bridgewater JA.

J Clin Oncol. 2015 Jul 20;33(21):2405-6. doi: 10.1200/JCO.2014.60.1344. Epub 2015 Jun 1. No abstract available.

PMID:
26033821
34.

The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis.

Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock M, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose J, Packham G, Liu K, Bojja K, Gafà R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami A, Calin GA, Nicoloso MS.

Gut. 2016 Jun;65(6):977-989. doi: 10.1136/gutjnl-2015-309372. Epub 2015 Mar 24.

35.

Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs.

Bullock MD, Pickard K, Mitter R, Sayan AE, Primrose JN, Ivan C, Calin GA, Thomas GJ, Packham GK, Mirnezami AH.

Oncotarget. 2015 Mar 30;6(9):7262-79.

36.

Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma.

Underwood TJ, Hayden AL, Derouet M, Garcia E, Noble F, White MJ, Thirdborough S, Mead A, Clemons N, Mellone M, Uzoho C, Primrose JN, Blaydes JP, Thomas GJ.

J Pathol. 2015 Feb;235(3):466-77. doi: 10.1002/path.4467.

37.

Carcinoembryonic antigen monitoring to detect recurrence of colorectal cancer: how should we interpret the test results?

Shinkins B, Nicholson BD, James TJ, Primrose JN, Mant D.

Clin Chem. 2014 Dec;60(12):1572-4. doi: 10.1373/clinchem.2014.228601. Epub 2014 Aug 26. No abstract available.

38.

Cetuximab for resectable colorectal liver metastasis: new EPOC trial--author's reply.

Primrose JN.

Lancet Oncol. 2014 Jul;15(8):e306. doi: 10.1016/S1470-2045(14)70241-4. No abstract available.

PMID:
24988933
39.

CEA monitoring in colorectal cancer is not a waste of time.

Mant D, Primrose J.

BMJ. 2014 Jun 18;348:g4032. doi: 10.1136/bmj.g4032. No abstract available.

PMID:
24944045
40.

A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.

Bao T, Goloubeva O, Pelser C, Porter N, Primrose J, Hester L, Sadowska M, Lapidus R, Medeiros M, Lao L, Dorsey SG, Badros AZ.

Integr Cancer Ther. 2014 Sep;13(5):396-404. doi: 10.1177/1534735414534729. Epub 2014 May 26.

41.

Surveillance for recurrence of colorectal cancer--reply.

Primrose JN, Mant D.

JAMA. 2014 May;311(20):2128. doi: 10.1001/jama.2014.3417. No abstract available.

PMID:
24867020
42.

Molecular profiling of the invasive tumor microenvironment in a 3-dimensional model of colorectal cancer cells and ex vivo fibroblasts.

Bullock MD, Mellone M, Pickard KM, Sayan AE, Mitter R, Primrose JN, Packham GK, Thomas G, Mirnezami AH.

J Vis Exp. 2014 Apr 29;(86). doi: 10.3791/51475.

43.

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.

Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T, Butler R, Stanton L, Dixon E, Little L, Bowers M, Pugh S, Garden OJ, Cunningham D, Maughan T, Bridgewater J.

Lancet Oncol. 2014 May;15(6):601-11. doi: 10.1016/S1470-2045(14)70105-6. Epub 2014 Apr 7. Erratum in: Lancet Oncol. 2014 Jun;15(7):e253.

PMID:
24717919
44.

T cells but not NK cells are associated with a favourable outcome for resected colorectal liver metastases.

Pugh SA, Harrison RJ, Primrose JN, Khakoo SI.

BMC Cancer. 2014 Mar 13;14:180. doi: 10.1186/1471-2407-14-180.

45.

The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation.

Loveman E, Jones J, Clegg AJ, Picot J, Colquitt JL, Mendes D, Breen DJ, Moore E, George S, Poston G, Cunningham D, Ruers T, Primrose J.

Health Technol Assess. 2014 Jan;18(7):vii-viii, 1-283. doi: 10.3310/hta18070. Review.

46.

Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.

Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, George S, Mant D; FACS Trial Investigators.

JAMA. 2014 Jan 15;311(3):263-70. doi: 10.1001/jama.2013.285718.

PMID:
24430319
47.

Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.

Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, Webb A, Hampton C, Patel NN, Randall CJ, Cox HJ, Jogai S, Primrose J, Piper K, Ottensmeier CH, King EV, Thomas GJ.

Br J Cancer. 2014 Jan 21;110(2):489-500. doi: 10.1038/bjc.2013.639. Epub 2013 Oct 29.

48.

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und–tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD).

Lancet Oncol. 2013 Nov;14(12):1208-15. doi: 10.1016/S1470-2045(13)70447-9. Epub 2013 Oct 11.

PMID:
24120480
49.

miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.

Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J, Thomas GJ, Packham G, Mirnezami AH.

Cancer Res. 2013 Nov 1;73(21):6435-47. doi: 10.1158/0008-5472.CAN-12-3308. Epub 2013 Aug 15.

50.

FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role.

Bullock MD, Bruce A, Sreekumar R, Curtis N, Cheung T, Reading I, Primrose JN, Ottensmeier C, Packham GK, Thomas G, Mirnezami AH.

Br J Cancer. 2013 Jul 23;109(2):387-94. doi: 10.1038/bjc.2013.355. Epub 2013 Jul 4.

Supplemental Content

Loading ...
Support Center